| Followers | 843 |
| Posts | 122898 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Thursday, April 24, 2014 3:23:36 PM
If you don't own the stock, what is your purpose for posting here?
1. GILD is the main competitor to a company in which I own a large position (ENTA).
2. I may buy GILD at some point; I need to stay abreast of developments to be able to strike if the opportunity presents itself.
Moreover, GILD is a stock that many serious biotech investors follow whether or not they have a position. With a $110B+ market cap, GILD is one of the bellwether companies in the sector. The Sovaldi launch has attracted so much publicity and generated so much political agitation that it’s affected the entire biotech arena and the entire US stock market to some degree.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent GILD News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 08:12:50 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/28/2026 01:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 12:56:25 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/28/2026 12:53:40 PM
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel • Business Wire • 04/28/2026 12:45:00 PM
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 • Business Wire • 04/22/2026 08:05:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/17/2026 01:00:24 PM
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer • Business Wire • 04/17/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:40:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:08:03 PM
- PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access • Business Wire • 04/14/2026 04:00:00 PM
- Tempus AI Shares Gain After Expanded Partnership with Gilead • IH Market News • 04/10/2026 01:34:23 PM
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline • Business Wire • 04/07/2026 12:30:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:34:18 PM
- Gilead Extends Tender Offer to Acquire Arcellx • Business Wire • 04/01/2026 08:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 09:59:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:03:17 PM
- Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases • Business Wire • 03/23/2026 10:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:01:13 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (Canada) • 03/19/2026 02:00:00 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (US) • 03/19/2026 02:00:00 PM
